{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T13:46:14Z","timestamp":1782481574295,"version":"3.54.5"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","award":["LQ24H310011"],"award-info":[{"award-number":["LQ24H310011"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109956","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:21:52Z","timestamp":1778023312000},"page":"109956","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells"],"prefix":"10.1016","volume":"178","author":[{"given":"Wenying","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongchong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundixia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.109956_bb0005","doi-asserted-by":"crossref","first-page":"32368","DOI":"10.18632\/oncotarget.5941","article-title":"Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors","volume":"6","author":"Baldelli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109956_bb0010","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s13045-022-01375-4","article-title":"Drugging KRAS: current perspectives and state-of-art review","volume":"15","author":"Parikh","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.sbi.2021.06.013","article-title":"Stopping the beating heart of cancer: KRAS reviewed","volume":"71","author":"Herdeis","year":"2021","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0020","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.109956_bb0025","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40265-021-01574-2","article-title":"Sotorasib: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109956_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40265-023-01839-y","article-title":"Adagrasib: First Approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.109956_bb0035","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bioorg.2026.109956_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108050","article-title":"Resistance looms for KRAS G12C inhibitors and rational tackling strategies","volume":"229","author":"Zhang","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.109956_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12020325","article-title":"Abnormalities in the KRAS Gene and Treatment options for NSCLC patients with the G12C mutation in this Gene-a literature review and single-center experience","volume":"12","author":"Rekowska","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.109956_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119313","article-title":"KRAS-dependency in pancreatic ductal adenocarcinoma: mechanisms of escaping in resistance to KRAS inhibitors and perspectives of therapy","volume":"24","author":"Gurreri","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0055","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/carcin\/bgaa039","article-title":"NRF2 as a regulator of cell metabolism and inflammation in cancer","volume":"41","author":"He","year":"2020","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2026.109956_bb0060","doi-asserted-by":"crossref","first-page":"2746457","DOI":"10.1155\/2016\/2746457","article-title":"NRF2, a key regulator of antioxidants with two faces towards Cancer","volume":"2016","author":"Kim","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.109956_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122772","article-title":"Nrf2, the master regulator of anti-oxidative responses","volume":"18","author":"Vomund","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.mbplus.2021.100057","article-title":"The Nrf2 transcription factor: a multifaceted regulator of the extracellular matrix","volume":"10","author":"Hiebert","year":"2021","journal-title":"Matrix Biol. Plus"},{"key":"10.1016\/j.bioorg.2026.109956_bb0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.molmed.2016.05.002","article-title":"The dual roles of NRF2 in Cancer","volume":"22","author":"Menegon","year":"2016","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bioorg.2026.109956_bb0080","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1002\/cam4.2101","article-title":"Nrf2 in cancers: a double-edged sword","volume":"8","author":"Wu","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.bioorg.2026.109956_bb0085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","article-title":"Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2","volume":"29","author":"Wang","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bioorg.2026.109956_bb0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1042\/BST20150014","article-title":"Dissecting molecular cross-talk between Nrf2 and NF-kappaB response pathways","volume":"43","author":"Wardyn","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bioorg.2026.109956_bb0095","doi-asserted-by":"crossref","first-page":"3897250","DOI":"10.1155\/2016\/3897250","article-title":"The relevance of Nrf2 pathway and autophagy in pancreatic cancer cells upon stimulation of reactive oxygen species","volume":"2016","author":"Zhang","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.109956_bb0100","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J. Antibiot."},{"key":"10.1016\/j.bioorg.2026.109956_bb0105","first-page":"4916","article-title":"FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases","volume":"62","author":"Furumai","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109956_bb0110","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1345\/aph.1R036","article-title":"Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma","volume":"46","author":"Kim","year":"2012","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109956_bb0115","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00280-021-04298-y","article-title":"A triple combination gemcitabine plus romidepsin plus cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis","volume":"88","author":"Pattarawat","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0120","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/s41416-020-0877-8","article-title":"Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma","volume":"123","author":"Pattarawat","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109956_bb0125","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.7150\/jca.28570","article-title":"Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC","volume":"10","author":"Zhang","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.bioorg.2026.109956_bb0130","doi-asserted-by":"crossref","first-page":"69804","DOI":"10.18632\/oncotarget.12001","article-title":"Blocking downstream signaling pathways in the context of HDAC inhibition promotes apoptosis preferentially in cells harboring mutant Ras","volume":"7","author":"Bahr","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2026.109956_bb0135","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1111\/j.1349-7006.2010.01645.x","article-title":"Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide","volume":"101","author":"Mizutani","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0140","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2217\/fon-2022-1106","article-title":"Adagrasib: a novel inhibitor for KRASG12C-mutated non-small-cell lung cancer","volume":"19","author":"Guo","year":"2023","journal-title":"Future Oncol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0145","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1158\/2159-8290.CD-24-0217","article-title":"Efficacy and safety of Adagrasib plus Cetuximab in patients with KRASG12C-mutated metastatic colorectal Cancer","volume":"14","author":"Yaeger","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bioorg.2026.109956_bb0150","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1078-0432.CCR-24-2310","article-title":"Impact of co-mutations and transcriptional signatures in non-small cell lung Cancer patients treated with Adagrasib in the KRYSTAL-1 trial","volume":"31","author":"Negrao","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109956_bb0155","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41420-025-02657-9","article-title":"Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer","volume":"11","author":"Lu","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bioorg.2026.109956_bb0160","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2026.109956_bb0165","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.109956_bb0170","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-020-02653-1","article-title":"Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer","volume":"70","author":"Shi","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bioorg.2026.109956_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114774","article-title":"Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin","volume":"164","author":"El Omari","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bioorg.2026.109956_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.156143","article-title":"Fangchinoline suppresses hepatocellular carcinoma by regulating ROS accumulation via the TRIM7\/Nrf2 signaling pathway","volume":"135","author":"Liu","year":"2024","journal-title":"Phytomedicine"},{"key":"10.1016\/j.bioorg.2026.109956_bb0185","doi-asserted-by":"crossref","first-page":"30165","DOI":"10.1038\/s41598-024-81375-1","article-title":"Nrf2 depletion enhanced curcumin therapy effect in gastric cancer by inducing the excessive accumulation of ROS","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.109956_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13046-020-01620-z","article-title":"BDH2 triggers ROS-induced cell death and autophagy by promoting Nrf2 ubiquitination in gastric cancer","volume":"39","author":"Liu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109956_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205081","article-title":"Escaping KRAS: gaining autonomy and resistance to KRAS inhibition in KRAS mutant cancers","volume":"13","author":"Adachi","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2026.109956_bb0200","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s12272-020-01298-z","article-title":"NRF2 level is negatively correlated with TGF-beta1-induced lung cancer motility and migration via NOX4-ROS signaling","volume":"43","author":"Ryu","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.bioorg.2026.109956_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102224","article-title":"Inhibition of GCN2 alleviates hepatic steatosis and oxidative stress in obese mice: involvement of NRF2 regulation","volume":"49","author":"Yuan","year":"2022","journal-title":"Redox Biol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-024-07194-4","article-title":"DeltaNp63alpha promotes radioresistance in esophageal squamous cell carcinoma through the PLEC-KEAP1-NRF2 feedback loop","volume":"15","author":"Tao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109956_bb0215","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/s41401-022-01015-0","article-title":"Targeting PI3Kalpha overcomes resistance to KRas(G12C) inhibitors mediated by activation of EGFR and\/or IGF1R","volume":"44","author":"Qi","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bioorg.2026.109956_bb0220","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung Cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2026.109956_bb0225","doi-asserted-by":"crossref","first-page":"5583215","DOI":"10.1155\/2021\/5583215","article-title":"Reactive oxygen species as a link between antioxidant pathways and autophagy","volume":"2021","author":"Li","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.109956_bb0230","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.7150\/ijbs.103187","article-title":"The crosstalk between autophagy and Nrf2 signaling in Cancer: from biology to clinical applications","volume":"20","author":"Shan","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0235","doi-asserted-by":"crossref","first-page":"1232241","DOI":"10.3389\/fcell.2023.1232241","article-title":"An update on the bridging factors connecting autophagy and Nrf2 antioxidant pathway","volume":"11","author":"Ning","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0240","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.trecan.2024.11.009","article-title":"KRAS inhibitors: resistance drivers and combinatorial strategies","volume":"11","author":"Isermann","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bioorg.2026.109956_bb0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-022-01629-2","article-title":"Targeting KRAS mutant cancers: from druggable therapy to drug resistance","volume":"21","author":"Zhu","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bioorg.2026.109956_bb0250","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.787585","article-title":"Resistance to KRAS(G12C) inhibitors in non-small cell lung Cancer","volume":"11","author":"Blaquier","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0255","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-19-1363","article-title":"Undermining Glutaminolysis bolsters chemotherapy while NRF2 promotes Chemoresistance in KRAS-driven pancreatic cancers","volume":"80","author":"Mukhopadhyay","year":"2020","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.bioorg.2026.109956_bb0260","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.arbres.2024.06.021","article-title":"NRF2 signaling pathway in chemo\/radio\/Immuno-therapy resistance of lung Cancer: looking beyond the tip of the iceberg","volume":"60","author":"Ramisetti","year":"2024","journal-title":"Arch. Bronconeumol."},{"key":"10.1016\/j.bioorg.2026.109956_bb0265","article-title":"Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer","volume":"13","author":"Bartolacci","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.109956_bb0270","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41419-021-03473-6","article-title":"Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesis","volume":"12","author":"Liu","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.109956_bb0275","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.3724\/abbs.2022173","article-title":"KRAS G12D mutation eliminates reactive oxygen species through the Nrf2\/CSE\/H (2)S axis and contributes to pancreatic cancer growth","volume":"54","author":"Fan","year":"2022","journal-title":"Acta Biochim. Biophys. Sin. Shanghai"},{"key":"10.1016\/j.bioorg.2026.109956_bb0280","article-title":"Reactive oxygen species mediate 6c-induced mitochondrial and lysosomal dysfunction, Autophagic cell death, and DNA damage in hepatocellular carcinoma","volume":"22","author":"Wang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cells14151207","article-title":"Reactive oxygen species: a double-edged sword in the modulation of Cancer signaling pathway dynamics","volume":"14","author":"Nigam","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.109956_bb0290","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1021\/acs.molpharmaceut.3c00926","article-title":"Nanoencapsulation of MDM2 inhibitor RG7388 and class-I HDAC inhibitor Entinostat enhances their therapeutic potential through synergistic antitumor effects and reduction of systemic toxicity","volume":"21","author":"Abed","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2026.109956_bb0295","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/blood.2024027997","article-title":"Nanoromidepsin, a polymer nanoparticle of the HDAC inhibitor, improves safety and efficacy in models of T-cell lymphoma","volume":"146","author":"Pal","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.109956_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107043","article-title":"Enhancement of the in vitro anti-leukemic effect of the histone deacetylase inhibitor romidepsin using poly-(D, L-lactide-co-glycolide) nanoparticles as a drug carrier","volume":"207","author":"Aroonthongsawat","year":"2025","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0305","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","article-title":"Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.bioorg.2026.109956_bb0310","first-page":"1352","article-title":"Co-targeting SOS1 enhances the antitumor effects of KRAS(G12C) inhibitors by addressing intrinsic and acquired resistance","volume":"5","author":"Thatikonda","year":"2024","journal-title":"Nat. Can."},{"key":"10.1016\/j.bioorg.2026.109956_bb0315","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12001","article-title":"A combination of PD-1\/PD-L1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy (review)","volume":"23","author":"Kong","year":"2021","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2026.109956_bb0320","doi-asserted-by":"crossref","first-page":"204","DOI":"10.7150\/ijbs.22955","article-title":"Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes","volume":"14","author":"Yang","year":"2018","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bioorg.2026.109956_bb0325","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00408-025-00801-x","article-title":"Update 2025: Management of non-Small-Cell Lung Cancer","volume":"203","author":"Jeon","year":"2025","journal-title":"Lung"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600492X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682600492X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:50:19Z","timestamp":1782478219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682600492X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"alternative-id":["S004520682600492X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109956","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Romidepsin inhibits NRF2 and enhances the efficacy of adagrasib by inducing autophagic cell death in KRAS-mutant tumor cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109956","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109956"}}